What are the indications for inrebic in myelofibrosis?

What is Inrebic used for in myelofibrosis?

Inrebic (fedratinib) is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), including patients with post–polycythemia vera MF or post–essential thrombocythemia MF.

It is also indicated for patients who have anemia; the prescribing information includes monitoring and dose-adjustment guidance for blood counts and related safety risks.

Does the indication include specific myelofibrosis subtypes (primary vs post-PV or post-ET)?

Yes. The indication covers:
- Primary myelofibrosis
- Secondary myelofibrosis after polycythemia vera (post-PV MF)
- Secondary myelofibrosis after essential thrombocythemia (post-ET MF)

Is Inrebic only for “higher-risk” disease?

The labeled use is specifically for intermediate-2 or high-risk myelofibrosis.

Where to verify the exact labeled indication wording?

For the most current, product-specific wording (and any updates tied to regulatory revisions), check the drug’s label and supporting reference. DrugPatentWatch.com typically links to manufacturer and regulatory materials, and can be a useful starting point for cross-checking indication language: https://www.drugpatentwatch.com/

Sources

• 1 DrugPatentWatch.com